secwatch.observer — SEC 8-K summary
======================================

Issuer:     Organogenesis Holdings Inc. (ORGO)
CIK:        0001661181
Form:       8-K
Filed at:   2021-11-09T23:59:59+00:00
Accession:  0001193125-21-324457
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Organogenesis Q3 revenue $113.8M (+13% YoY), net income $12.6M, FY2021 guidance $458-470M
--------------------------------------------------------------------------------

- Net revenue $113.8M (+13% YoY); Advanced Wound Care $107.3M (+19%), Surgical & Sports Medicine $6.4M (-41%).
- Net income $12.6M ($0.09 diluted EPS) vs $20.8M ($0.19) in Q3 2020; adj. EBITDA $21.7M (19% margin).
- FY2021 guidance: net revenue $458-470M (35-39% growth); Advanced Wound Care $425-434M, PuraPly $196-204M.
- Cash $102.7M, debt $83.2M as of Sept 30, 2021.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1661181/000119312521324457/0001193125-21-324457-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1661181/000119312521324457/d234616d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-21-324457

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer